enkemm
Nov 12, 6:56 PM
$INKT In addition, the therapy must be intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition.
Finally, early clinical data must show that the therapy has the potential to address unmet medical needs for that condition. Unlike Breakthrough Therapy designation, RMAT does not require evidence proving the drug is a substantial improvement over existing treatments.
The key benefits from a RMAT designation are that it provides all the benefits of the FDA's Fast Track and Breakthrough Therapy programs.
Also, sponsors receive meetings with senior FDA managers to design efficient clinical trials, and developers can discuss using surrogate or intermediate endpoints to support accelerated approval, rather than waiting years for traditional long-term clinical outcomes. Additionally, there are flexible ways to satisfy post-approval study requirements, including using real-world evidence, patient registries, or electronic health records.
Page 2
0 replies